Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies

• Published in: Journal of oncology Vol. 2022; pp. 1 - 10
• Main Authors: An, Ye, Sun, Jian-Xuan, Xu, Meng-Yao, Liu, Chen-Qian, Xu, Jin-Zhou, Zhong, Xing-Yu, Hu, Jia, Xia, Qi-Dong, Hu, Heng-Long, Wang, Shao-Gang
• Format: Journal Article
• Language: English
• Published: New York Hindawi 15.11.2022; John Wiley & Sons, Inc
• Subjects: Analysis; Bias; Cancer; Cancer patients; Cancer therapies; Cohort analysis; Health aspects; Medical prognosis; Meta-analysis; Mortality; Oncology, Experimental; Prevention; Prognosis; Prostate cancer; Radiation therapy; Review; Statins; Statistical significance; Systematic review
• DOI: 10.1155/2022/9275466
• ISSN: 1687-8450

Objective. Although the prognostic effect of statins on patients with prostate cancer (PCa) has been frequently evaluated, a consistent result is still lacking. We aimed to evaluate the association between statin use and mortality among patients with PCa after definite therapies. Methods. A systematic search of PubMed and other databases for cohort studies about the effect of statins on patients with PCa was performed until April 2022. Meta-analysis was performed using R software version 4.1.2. Results. 24 cohort studies involving 369, 206 participants were finally included. We found statin use significantly reduced the risk of prostate cancer-specific mortality (PCSM) with a pooled hazard ratio (pHR) = 0.76 (95% CI: 0.69–0.84, 18 studies), especially for postdiagnostic statin users: pHR = 0.81 (95% CI: 0.77–0.85) and patients who accepted androgen deprivation therapy (ADT): pHR = 0.69 (95% CI: 0.59–0.81). Statin use was also associated with a 24% reduction in the risk of all-cause mortality (ACM): pHR = 0.76 (95% CI: 0.68–0.85, 17 studies), especially for postdiagnostic statin users: pHR = 0.81 (95% CI: 0.78–0.85) and patients treated with ADT: pHR = 0.72 (95% CI: 0.63–0.82) or radiotherapy (RT): pHR = 0.68 (95% CI: 0.50–0.93). Conclusion. In conclusion, the use of statins could promote the prognosis of patients with PCa, especially for postdiagnostic users. For patients who received either ADT or radical prostatectomy (RP), statin use could decrease the PCSM. As for those who received either ADT or RT, statin use could decrease the ACM.